Navigation Links
KBioBox Wins Multi Year License Agreement to Provide Poseida Therapeutics Inc with Custom Bioinformatic Analysis for Genetic Data.
Date:1/11/2017

KBioBox llc is pleased to announce today that it has signed a multi-year license agreement with Poseida Therapeutics Inc, the San Diego based specialist in gene and cell therapy programs, to provide custom bioinformatics analysis for genetic data. Poseida Therapeutics selected KBioBox in order to harness KBioBox’s powerful BioEngine Algorithms which do not compromise speed for accuracy. The system was custom developed using client determined parameters and annotated results format.

Recently KBioBox announced the launch of its genetic data bioInformatics portal.

In response to client demand KBioBox developed a sophisticated “3 click” gene editing off target analysis program and a “3 Click” gene edit design program. Both are accessible from KBioBox’s new website, https://www.kbiobox.com/ and powered by the company’s proprietary BioEngine. Scientists, pharmaceutical researchers and academics can access the portal and enter their own gene edit off target analysis project for free and have clear, actionable results in minutes. Simple to use with high value output. https://www.kbiobox.com/freeofftargetanalysis

For "gene edit off target analysis" enter a) Cell line b) Gene edit type c) Design.
In under a minute the KBioBox BioEngine searches the whole genome for Off Targets and produces an annotated, easy-to- understand report with intuitive visualizations and all locus information provided:
Video. http://www.kbiobox.com/offtarget?autoplay=true#ota-video

For "gene edit design analysis" enter a) Location b) Search type c) Gene edit type.
In under a minute the KBioBox BioEngine determines the “top ten” designs and produces an easy-to-understand interactive report with intuitive visualizations and whole genome off target analysis for each design:
Video http://www.kbiobox.com/biodesign?autoplay=true#biodesign-video

About KBioBox llc

KBioBox is a technology company with expertsie in BioInformatics specialising in fast precision off target analysis and gene edit biodesign. Created in reponse to the growing need for real-time genetic sequence analysis, KBioBox's BioEngine is a powerful genomic search engine capable of searching entire genomes in minutes for even the most complex searches. BioEngine technology is built upon novel proprietary search algorythms that do not compromise speed for accuracy. Simple interactiveness and minimal computation requirements mean the technology can be used in the field or in the cloud or accessed through the portal. Clients can run "one off" reports or license the technology ( software) for multi-projects and multi-subscription periods.

KBioBox technology is customizable to any Bioinformatics application. Scientists can take advantage of the BioEngine to empower research and improve the quality of results in a significantly shorter period.

Application areas include not only "gene editing biodesign" and "off target analysis but also cell line engineering, microbiome, oncology, diagnostics and annotations.

Technical applications include BioEngine technology, Wen API, empowering existing bioinformatics and and cloud BioEngine.

Technologies include " off target analysis", "gene edit design" and pathogen identification/analysis.

About Poseida Therapeutics Inc.
Please visit http://poseida.com/about-us/

Read the full story at http://www.prweb.com/releases/2017/01/prweb13969643.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. KBioBox Launches First Genetic Data BioInformatics Portal Accessible to Scientists for Off Target and Gene Edit Design Analysis. (Complimentary Trial)
2. Heidelberg Instruments GmbH, Wins a Multi-Million Dollar Capital Equipment Order From Japan
3. Groundbreaking MMRF CoMMpass Study(SM) Affirmed as Premier Genomics Data Set in Multiple Myeloma
4. New Clinical Study Demonstrates Feasibility of Performing Multiplex ANA Testing on Whole Blood via Finger-Stick in Physician Office Near-Patient Setting
5. PharmaMar annuncia al Congresso ASCO i risultati positivi dello studio di Fase I della plitidepsina in combinazione con bortezomib e desametasone in pazienti affetti da mieloma multiplo
6. MIT Team bioLogic Wins Multiple Design Awards with Extraordinary Living Textile that Transform Based on Users' Needs
7. Cirrascale Expands Multi-GPU Deep Learning Solutions with NVIDIA DGX-1 Deep Learning System
8. Cirrascale® Launches Innovative Multi-GPU Cloud Service Aimed at Tackling Multi-GPU Deep Learning Training Applications
9. Cirrascale® Expands Multi-GPU Deep Learning Solutions with Support for Latest Addition to NVIDIA Tesla Accelerated Computing Platform
10. EarlySense Launches New Multi-Parameter Alert to Support Hospital Sepsis Protocol
11. During Multiple Sclerosis Awareness Month, MSWorld Celebrates Individuals and Groups Who Empower People with MS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... -- On Thursday, March 23, 2017, the ... 0.07%; the Dow Jones Industrial Average edged 0.02% lower, ... at 2,345.96, marginally dropping 0.11%. US markets saw a ... sectors finished in red, and 1 sector ended flat ... coverage on the following Biotechnology equities: BioDelivery Sciences International ...
(Date:3/23/2017)... Research and Markets has announced the addition of ... offering. ... The Global Market for Bioproducts Should Reach $714.6 Billion ... of 8.9%, This research report quantifies the ... product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), biocomposite ...
(Date:3/23/2017)... ... 23, 2017 , ... Ellen Matloff, president and CEO of ... as a 2017 Women of Innovation® finalist. Matloff will be among several women ... The dinner recognizes women accomplished in science, technology, engineering and math (STEM), along ...
(Date:3/23/2017)... 2017 In today,s pre-market research, ... the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate ... SYN), and Regulus Therapeutics Inc. (NASDAQ: RGLS ... Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn ... at: ...
Breaking Biology Technology:
(Date:3/22/2017)... 21, 2017 Vigilant Solutions , a ... enforcement agencies, announced today the appointment of retired FBI ... public safety business development. Mr. Sheridan brings ... including a focus on the aviation transportation sector, to ... position, Mr. Sheridan served as the Aviation Liaison Agent ...
(Date:3/9/2017)... , Australia , March 9, ... study data at the prestigious World Lung Imaging Workshop ... Andreas Fouras , was invited to deliver the ... pulmonary medicine. This globally recognised event brings together leaders ... share the latest developments in lung imaging. ...
(Date:3/2/2017)... YORK , March 2, 2017 Summary ... better understand Perrigo and its partnering interests and activities since ... ... Partnering Deals and Alliance since 2010 report provides an in-depth ... leading life sciences companies. On demand company reports ...
Breaking Biology News(10 mins):